Shahir Kassam-Adams is one of the most knowledgeable and outspoken people in healthcare. In this episode, Shahir shares his initially unsettling but ultimately reassuring view that “data will eat public health.” He opines on interoperability and explains how his company, Datavant has promoted data sharing on COVID-19, leading to a plethora of interesting and potentially useful projects, including one that models the tradeoffs for specific American cities to reopen.
CareCentrix CEO, John Driscoll and I talk #CareTalk on the road to the HLTH conference in Las Vegas, where we interviewed some big names include Obamacare architect Zeke Emmanuel, Former CMS Administrator Andy Slavitt, Former Congressman Patrick Kennedy, Walmart Health exec Marcus Osborne, and Boston Children’s Chief Innovation Officer John Brownstein.
You can check out the whole series on the YouTube playlist.
Steve Wiggins has seen a thing or two in his more than three decades as a healthcare entrepreneur. His Oxford Health Plans introduced “pods,” a precursor of the Accountable Care Organization and he led HealthMarket, an early player in the consumer directed health plan space. He’s carried the same themes into his current role as founder and Chairman of Remedy Partners, the leader in Medicare’s Bundled Payments for Care Initiative (BPCI).
As you’ll hear in this podcast, Steve’s a big believer in bundles, offering them as a proven solution for a large portion of the healthcare dollar, within almost any healthcare financing framework from traditional commercial coverage to Medicare for All.
Here’s what we discussed:
(0:18) What is a bundled payment? How does it relate to other new approaches like ACOs?
(3:05) Did bundled payments start in Medicare rather than the private sector? If so, why?
(6:52) How well has BPCI worked? What does the future look like?
(11:01) How do episodes and bundles tie in more broadly? I often hear that chronic care or end of life care are the big cost drivers, not episodic care. Can those statements be reconciled?
(15:10) How should we think about bundled payments and related topics playing into the campaign, or should we just give up on that?
(19:14) You’ve founded quite a few healthcare companies over your career. How does this Remedy compare?
(21:41) How do you expect the company to evolve in the next few years?
Belong.life bills itself as the largest social network for cancer patients and caregivers. With over 100,000 participants, Belong is approaching the scale at which it can generate meaningful insights, and leverage machine learning and artificial intelligence to create a “hyper-personalized” experience.
I spoke recently with Irad Deutsch, Chief Technology Officer. He described how his personal experience as a caregiver led him to co-found the company, and talked about what makes Belong valuable and differentiated.
(0:12) What are some of the main unmet needs for cancer patients and caregivers? Why was there a need for Belong in the first place?
(2:15) What, specifically does Belong do for patients that they can’t get elsewhere?
(4:23) How are providers and payers involved with Belong? Is this mainly a branding and cost-saving tool for them?
(7:03) What about pharmaceutical companies?
(8:00) You recently released a cancer fatigue survey. Why did you conduct that and what did it show? Any real surprises?
(10:08) You talk a lot about big data and machine learning but it’s not readily evident how those play in to Belong. Can you explain?
What’s worse than needing help with gait, mobility and balance? Being told you need a walker. No wonder, when the typical walker basically screams “frail elderly,” and is difficult to use as well.
Neurologist Patricia Kavanagh was struggling to get her patients with Parkinson’s and other movement disorders to use a walker. So she teamed up with a design and production team to found Foray and create the Spring, a modern device that is more functional and stylish.
In this podcast interview we discuss:
(0:13) Dr. Kavanagh’s clinical practice and the types of patients she treats
(1:19) Key challenges she faces working with patients with movement disorders
(3:24) Problems with current assistive devices like canes and walkers
(6:11) Whether walkers are unique in their poor design
(7:26) The story behind the birth of Foray and the development of the Spring
(8:42) The target audience
(12:04) Price point for the new device
(12:50) The thinking behind the branding of Spring and Foray
(13:31) Potential line extensions
(15:20) Impact of burden of chronic disease on mobility and exercise tolerance